Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ECE1 | P42892 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.31 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.31 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.31 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2019186 | 1.00 | USP2 (0.37) | USP2TSHRKMT2AMEN1ALDH1A1 | |
| SCHEMBL13687952 | 0.80 | KMT2A (0.54) | USP2TSHRKMT2AMEN1ALDH1A1 | |
| SCHEMBL8037489 | 0.79 | — | — | |
| SCHEMBL13902934 | 0.79 | USP2 (0.39) | USP2TSHRKMT2AMEN1ALDH1A1 | |
| SCHEMBL15791951 | 0.79 | CYP2D6 (0.35) | USP2TSHRKMT2AMEN1ALDH1A1 | |
| SCHEMBL8956500 | 0.78 | USP2 (0.37) | USP2TSHRKMT2AMEN1ALDH1A1 | |
| SCHEMBL27738883 | 0.77 | — | — | |
| SCHEMBL15801447 | 0.76 | — | — | |
| SCHEMBL17694106 | 0.75 | DPP7 (0.55) | DPP7 | |
| SCHEMBL19580046 | 0.75 | MEN1 (0.46) | USP2TSHRKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160180-A1 | Cannabinoid Receptor Ligands | ASTRAZENECA AB (SE) | 2011-06-30 | — | — | US | disclosed |
| US-20110160180-A1 | Cannabinoid Receptor Ligands | ASTRAZENECA AB (SE) | 2011-06-30 | — | — | US | disclosed |
| US-20110160180-A1 | Cannabinoid Receptor Ligands | ASTRAZENECA AB (SE) | 2011-06-30 | — | — | US | disclosed |
| EP-2190838-A1 | CANNABINOID RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2010-06-02 | — | — | EP | disclosed |
| US-20090062251-A1 | Novel Compounds 002 | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| WO-2009024819-A1 | CANNABINOID RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009024819-A1 | CANNABINOID RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062251-A1 | Novel Compounds 002 | OPRL1, OPRK1, OPRM1 | USP2 4486/4885TSHR 2124/4885KMT2A 2567/4885 |
| US-20110160180-A1 | Cannabinoid Receptor Ligands | CNR1, CNR2, OPRL1 | USP2 3947/4885TSHR 392/4885KMT2A 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.